Story perspectives

FDA OKs Zyn as Lower-Risk, Sparks Lung Group Outcry

6/30/2026

Summary

Story summary

FDA authorized Zyn nicotine pouches as lower-risk than cigarettes, the first reduced-risk claim for nicotine pouch.
The agency required Swedish Match USA to run a five-year risk study and warned it could revoke the claim if youth use rises.
The American Lung Association called the decision appalling and urged reversal to protect children.
President Donald Trump’s administration is easing nicotine-product restrictions, a shift industry says supports Zyn’s growth.

History

Historical Context

After the 2009 Family Smoking Prevention and Tobacco Control Act—signed by President Obama and spawning the FDA’s Center for Tobacco Products (opened Aug 19, 2009)—the agency expanded authority with the 2016 deeming rule and a 2022 clarification covering synthetic nicotine. In 2024 the FDA approved Swedish Match USA’s Zyn nicotine pouches, mandating a five-year, $10 million youth-impact study that could dictate future reduced-risk product approvals.

1 of 2

Story summary

FDA authorized Zyn nicotine pouches as lower-risk than cigarettes, the first reduced-risk claim for nicotine pouch.
The agency required Swedish Match USA to run a five-year risk study and warned it could revoke the claim if youth use rises.
The American Lung Association called the decision appalling and urged reversal to protect children.
President Donald Trump’s administration is easing nicotine-product restrictions, a shift industry says supports Zyn’s growth.

1 / 2